Longeveron's Heart Drug Misses Phase 2b Goal, Triggering Strategic Review
Longeveron's ELPIS II Phase 2b trial of laromstrocel in HLHS infants missed its primary endpoint. The company has launched a strategic review, plans to hire an investment bank and cut spending.